CCR

亜型選択性的な製品

CCR1 CCR2 CCR3 CCR4 CCR5 CCR8 CCL

シグナル伝達経路

CCR製品

All (29)
CCR阻害剤 (8)
CCR抗体(4)
CCR拮抗剤(15)
CCR作動薬(1)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S2003	Maraviroc	Maraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.	Commun Biol, 2024, 7(1):488 Commun Biol, 2024, 7(1):488 iScience, 2024, 27(7):110141
S2907	Pirfenidone	Pirfenidone is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Pirfenidone attenuates chemokine (CC motif) ligand-2 (CCL2) and CCL12 production with anti-fibrotic activity. Phase 3.	Eur Respir J, 2024, 2300580 Phytomedicine, 2024, 135:156051 Phytomedicine, 2024, 133:155871
S3032	Bindarit	ビンダリットは、独特な抗炎症性活動が単球走化性タンパク質MCP-1/CCL2、MCP-3/CCL7とMCP-2/CCL8を含む炎症性ケモカインの亜族の選択的な抑制のためにある最初の合成物です。NMRとHPLCによって確かめられる品質。顧客レビュー、確認と紙表彰状を見てください。	Exp Mol Med, 2024, 56(2):408-421. J Biol Chem, 2023, S0021-9258(23)02393-1 Cell Death Discov, 2022, 8(1):466
S8512	Cenicriviroc	Cenicriviroc is a potent, orally active dual inhibitor of CC chemokine receptor 2 (CCR2) and CCR5. Cenicriviroc also inhibits HIV-1 and HIV-2 with potent anti-inflammatory and antiinfective activity.	Int J Biol Sci, 2023, 19(8):2572-2587 Stem Cells, 2023, 41(6):672-683 Life Science Alliance, 2023, 6(6)
S2004	Vicriviroc Malate	Vicriviroc is a potent CCR5 antagonist with IC50 of 0.91 nM, showing broad-spectrum activity against genetically diverse HIV-1 isolates, and also drug-resistant viruses with RTI, PRI, or MDR phenotypes. Phase 3.	Nature, 2013, 493(7430):51-5 Cancer Res, 2012, 72(15):3839-50 J Antimicrob Chemot, 2011, 66(4):802-12
S8501	Adaptavir (DAPTA)	Adaptavir (DAPTA, D-Ala-peptide T-amide, peptide T) is a water soluble potent, selective CCR5 antagonist which potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.	Cell Death Dis, 2022, 13(5):478 Proc Natl Acad Sci U S A, 2021, 118(9)e2017282118 FEBS J, 2020, 287(11):2367-2385
S8324	ZK756326 2HCl	ZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1.	Cancer Immunol Immunother, 2022, 10.1007/s00262-022-03196-3 J Exp Med, 2019, 216(12):2763-2777
S0129	SB-297006	SB-297006 is an antagonist of C-C chemokine receptor 3 (CCR3) that suppresses antigen-induced accumulation of T(h)2 as well as eosinophils in the lungs. SB-297006 suppressed CCL11-induced Th2 chemotaxis with IC50 of 2.5 μM.	JHEP Rep, 2023, 5(9):100805 JHEP Rep, 2023, 5(9):100805 Cell Death Dis, 2022, 13(5):478
S8220	INCB3344	INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.	MedComm (2020), 2024, 5(5):e535 Commun Biol, 2024, 7(1):488 Commun Biol, 2024, 7(1):488
S3383	RS102895	RS 102895 is a small molecule antagonist of CCR2 with an IC50 of 360 nM.	Exp Mol Med, 2024, 56(2):408-421. Theranostics, 2022, 12(17):7351-7370
S3494	Vicriviroc maleate	Vicriviroc maleate(SCH-417690 maleate,SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells.	Breast Cancer Res, 2021, 23(1):11
S6555	AZD2098	AZD2098 is a potent and bioavailable CCR4 receptor antagonist with pIC50 of 7.8.	Neurooncol Adv, 2022, 4(1):vdab194
S3479	R243	R243 is an inhibitor of Chemokine (C-C motif) receptor 8 (CCR8) signaling and chemotaxis.
E4715^New	SB-328437	SB-328437 is a non-peptide small molecule, potent and selective antagonist of CCR3 with an IC50 of 4.5 nM. It is important for eosinophil recruitment, a process that is thought to be crucial in the pathology of several inflammatory diseases including asthma, allergic rhinitis, and eczema.
S7604	BX471	BX471 (ZK811752, BAY 865047, SH T 04268H) is a potent nonpeptide CC chemokine receptor-1 (CCR1) antagonist with Ki values of 1 nM and 5.5 nM in both MIP-1α and MCP-3 binding to CCR1-transfected HEK293 cells, respectively.	Commun Biol, 2024, 7(1):1304
S7538	RS-102895 Hydrochloride	RS-102895 hydrochloride (HCl) is a potent antagonist of Chemokine (C-C motif) receptor 2 (CCR2) with IC50 of 360 nM, and shows no effect on CCR1. RS-102895 hydrochloride also inhibits human α1a and α1d receptors, rat brain cortex 5-HT1a receptor in cells with IC50s of 130 nM, 320 nM, 470 nM, respectively.
E0486	C-021	C-021 is a potent CCR4 antagonist with IC50 values are 0.14 μM and 39 nM for inhibition of chemotaxis in human and mouse respectively.
S0777	Isuzinaxib (APX-115 free base)	APX-115 free base (Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney.
A2630	Anti-CCR7 / CD197 (R707)	Anti-CCR7 / CD197 (R707) is a fully human antibody targeting CCR7 signaling and function. It exhibits the potential to prevent acute graft-versus-host disease (aGVHD).MW :145.36 KD.
S9738	RS504393	RS504393, an extremely selective CC chemokine receptor (CCR) 2 antagonist with IC50 of 98 nM, also targets multiple receptors for inhibition of CCR2b and CCR1 receptors when administrated in higher concentration.
S0085	BMS-813160	BMS-813160 is a potent, well-absorbed dual CCR2 and CCR5 chemokine antagonist. BMS-813160 inhibits inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation and invasion.	Commun Biol, 2024, 7(1):1304
E0395	Vercirnon	Vercirnon (GSK1605786A, CCX-282, Traficet-EN), an orally bioavailable, selective, and potent antagonist of CCR9, is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9.
S8361	PF-4136309	PF-4136309 (INCB8761, PF-04136309) is a potent, selective, and orally bioavailable CCR2 antagonist with an IC50 of 5.2 nM for human CCR2.
S0438^New	TAK-779	TAK-779(Takeda 779), a nonpeptide compound, is a potent antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5. It also exhibits highly potent and selective inhibition of R5 HIV-1 replication with EC50 and EC90 of 1.2 and 5.7 nM, respectively. It also suppresses the development of the cytokine storm in the murine model of the SARS-CoV-2-related acute respiratory distress syndrome.
A2568	Mogamulizumab (Anti-CCR4 / CD194)	Mogamulizumab (Anti-CCR4 / CD194) is a defucosylated humanized recombinant monoclonal antibody targeting CCR4. Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). MW:145.5 KD.
A2569	Plozalizumab (Anti-CCR2 / CD192)	Plozalizumab (Anti-CCR2 / CD192) is a specific humanized monoclonal antibody targeting CCR2. Plozalizumab can be used for malignant melanoma research. MW:145.5 KD.
A2040	Leronlimab (anti-CCR5)	Leronlimab (anti-CCR5)(PRO 140; Vyrologix) is a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. It is being investigated as a potential therapy in the treatment of HIV infection.
S3205	Perillaldehyde	Perillaldehyde (Perilladehyde, Perillal, PAE, PA), the main component of Perilla frutescens (a traditional medicinal antioxidant herb), inhibits BaP-induced AHR activation and ROS production, inhibits BaP/AHR-mediated release of the CCL2 chemokine, and activats the NRF2/HO1 antioxidant pathway.
S8324	ZK756326 2HCl	ZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1.	Cancer Immunol Immunother, 2022, 10.1007/s00262-022-03196-3 J Exp Med, 2019, 216(12):2763-2777
S2907	Pirfenidone	Pirfenidone is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Pirfenidone attenuates chemokine (CC motif) ligand-2 (CCL2) and CCL12 production with anti-fibrotic activity. Phase 3.	Eur Respir J, 2024, 2300580 Phytomedicine, 2024, 135:156051 Phytomedicine, 2024, 133:155871
S3032	Bindarit	ビンダリットは、独特な抗炎症性活動が単球走化性タンパク質MCP-1/CCL2、MCP-3/CCL7とMCP-2/CCL8を含む炎症性ケモカインの亜族の選択的な抑制のためにある最初の合成物です。NMRとHPLCによって確かめられる品質。顧客レビュー、確認と紙表彰状を見てください。	Exp Mol Med, 2024, 56(2):408-421. J Biol Chem, 2023, S0021-9258(23)02393-1 Cell Death Discov, 2022, 8(1):466
S8512	Cenicriviroc	Cenicriviroc is a potent, orally active dual inhibitor of CC chemokine receptor 2 (CCR2) and CCR5. Cenicriviroc also inhibits HIV-1 and HIV-2 with potent anti-inflammatory and antiinfective activity.	Int J Biol Sci, 2023, 19(8):2572-2587 Stem Cells, 2023, 41(6):672-683 Life Science Alliance, 2023, 6(6)
S2004	Vicriviroc Malate	Vicriviroc is a potent CCR5 antagonist with IC50 of 0.91 nM, showing broad-spectrum activity against genetically diverse HIV-1 isolates, and also drug-resistant viruses with RTI, PRI, or MDR phenotypes. Phase 3.	Nature, 2013, 493(7430):51-5 Cancer Res, 2012, 72(15):3839-50 J Antimicrob Chemot, 2011, 66(4):802-12
S3479	R243	R243 is an inhibitor of Chemokine (C-C motif) receptor 8 (CCR8) signaling and chemotaxis.
S7604	BX471	BX471 (ZK811752, BAY 865047, SH T 04268H) is a potent nonpeptide CC chemokine receptor-1 (CCR1) antagonist with Ki values of 1 nM and 5.5 nM in both MIP-1α and MCP-3 binding to CCR1-transfected HEK293 cells, respectively.	Commun Biol, 2024, 7(1):1304
S0777	Isuzinaxib (APX-115 free base)	APX-115 free base (Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney.
S3205	Perillaldehyde	Perillaldehyde (Perilladehyde, Perillal, PAE, PA), the main component of Perilla frutescens (a traditional medicinal antioxidant herb), inhibits BaP-induced AHR activation and ROS production, inhibits BaP/AHR-mediated release of the CCL2 chemokine, and activats the NRF2/HO1 antioxidant pathway.
A2630	Anti-CCR7 / CD197 (R707)	Anti-CCR7 / CD197 (R707) is a fully human antibody targeting CCR7 signaling and function. It exhibits the potential to prevent acute graft-versus-host disease (aGVHD).MW :145.36 KD.
A2568	Mogamulizumab (Anti-CCR4 / CD194)	Mogamulizumab (Anti-CCR4 / CD194) is a defucosylated humanized recombinant monoclonal antibody targeting CCR4. Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). MW:145.5 KD.
A2569	Plozalizumab (Anti-CCR2 / CD192)	Plozalizumab (Anti-CCR2 / CD192) is a specific humanized monoclonal antibody targeting CCR2. Plozalizumab can be used for malignant melanoma research. MW:145.5 KD.
A2040	Leronlimab (anti-CCR5)	Leronlimab (anti-CCR5)(PRO 140; Vyrologix) is a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. It is being investigated as a potential therapy in the treatment of HIV infection.
S2003	Maraviroc	Maraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.	Commun Biol, 2024, 7(1):488 Commun Biol, 2024, 7(1):488 iScience, 2024, 27(7):110141
S8501	Adaptavir (DAPTA)	Adaptavir (DAPTA, D-Ala-peptide T-amide, peptide T) is a water soluble potent, selective CCR5 antagonist which potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.	Cell Death Dis, 2022, 13(5):478 Proc Natl Acad Sci U S A, 2021, 118(9)e2017282118 FEBS J, 2020, 287(11):2367-2385
S0129	SB-297006	SB-297006 is an antagonist of C-C chemokine receptor 3 (CCR3) that suppresses antigen-induced accumulation of T(h)2 as well as eosinophils in the lungs. SB-297006 suppressed CCL11-induced Th2 chemotaxis with IC50 of 2.5 μM.	JHEP Rep, 2023, 5(9):100805 JHEP Rep, 2023, 5(9):100805 Cell Death Dis, 2022, 13(5):478
S8220	INCB3344	INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.	MedComm (2020), 2024, 5(5):e535 Commun Biol, 2024, 7(1):488 Commun Biol, 2024, 7(1):488
S3383	RS102895	RS 102895 is a small molecule antagonist of CCR2 with an IC50 of 360 nM.	Exp Mol Med, 2024, 56(2):408-421. Theranostics, 2022, 12(17):7351-7370
S3494	Vicriviroc maleate	Vicriviroc maleate(SCH-417690 maleate,SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells.	Breast Cancer Res, 2021, 23(1):11
S6555	AZD2098	AZD2098 is a potent and bioavailable CCR4 receptor antagonist with pIC50 of 7.8.	Neurooncol Adv, 2022, 4(1):vdab194
E4715^New	SB-328437	SB-328437 is a non-peptide small molecule, potent and selective antagonist of CCR3 with an IC50 of 4.5 nM. It is important for eosinophil recruitment, a process that is thought to be crucial in the pathology of several inflammatory diseases including asthma, allergic rhinitis, and eczema.
S7538	RS-102895 Hydrochloride	RS-102895 hydrochloride (HCl) is a potent antagonist of Chemokine (C-C motif) receptor 2 (CCR2) with IC50 of 360 nM, and shows no effect on CCR1. RS-102895 hydrochloride also inhibits human α1a and α1d receptors, rat brain cortex 5-HT1a receptor in cells with IC50s of 130 nM, 320 nM, 470 nM, respectively.
E0486	C-021	C-021 is a potent CCR4 antagonist with IC50 values are 0.14 μM and 39 nM for inhibition of chemotaxis in human and mouse respectively.
S9738	RS504393	RS504393, an extremely selective CC chemokine receptor (CCR) 2 antagonist with IC50 of 98 nM, also targets multiple receptors for inhibition of CCR2b and CCR1 receptors when administrated in higher concentration.
S0085	BMS-813160	BMS-813160 is a potent, well-absorbed dual CCR2 and CCR5 chemokine antagonist. BMS-813160 inhibits inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation and invasion.	Commun Biol, 2024, 7(1):1304
E0395	Vercirnon	Vercirnon (GSK1605786A, CCX-282, Traficet-EN), an orally bioavailable, selective, and potent antagonist of CCR9, is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9.
S8361	PF-4136309	PF-4136309 (INCB8761, PF-04136309) is a potent, selective, and orally bioavailable CCR2 antagonist with an IC50 of 5.2 nM for human CCR2.
S0438^New	TAK-779	TAK-779(Takeda 779), a nonpeptide compound, is a potent antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5. It also exhibits highly potent and selective inhibition of R5 HIV-1 replication with EC50 and EC90 of 1.2 and 5.7 nM, respectively. It also suppresses the development of the cytokine storm in the murine model of the SARS-CoV-2-related acute respiratory distress syndrome.
S8324	ZK756326 2HCl	ZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1.	Cancer Immunol Immunother, 2022, 10.1007/s00262-022-03196-3 J Exp Med, 2019, 216(12):2763-2777
E4715^New	SB-328437	SB-328437 is a non-peptide small molecule, potent and selective antagonist of CCR3 with an IC50 of 4.5 nM. It is important for eosinophil recruitment, a process that is thought to be crucial in the pathology of several inflammatory diseases including asthma, allergic rhinitis, and eczema.
S0438^New	TAK-779	TAK-779(Takeda 779), a nonpeptide compound, is a potent antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5. It also exhibits highly potent and selective inhibition of R5 HIV-1 replication with EC50 and EC90 of 1.2 and 5.7 nM, respectively. It also suppresses the development of the cytokine storm in the murine model of the SARS-CoV-2-related acute respiratory distress syndrome.

CCR阻害剤の選択性比較